Inflammation in multiple sclerosis: the good, the bad, and the complex (Q30810267)

26 June 2017

1 reference

title

Inflammation in multiple sclerosis: the good, the bad, and the complex (English)

1 reference

26 June 2017

0 references

0 references

Giancarlo Comi

1 reference

26 June 2017

Massimo Filippi

1 reference

26 June 2017

Peter Rieckmann

1 reference

26 June 2017

Gianvito Martino

1 reference

26 June 2017

Luciano Adorini

series ordinal

1 reference

26 June 2017

Jan Hillert

series ordinal

1 reference

26 June 2017

Boris Kallmann

series ordinal

1 reference

26 June 2017

publication date

1 December 2002

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

499-509

1 reference

Immunopathogenesis of multiple sclerosis: the role of T cells

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Effector pathways in immune mediated central nervous system demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

1 reference

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Gamma interferon activates a previously undescribed Ca2+ influx in T lymphocytes from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Elevated plasma endothelial microparticles in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

The Expression of Tissue-type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Myelin phagocytosis and remyelination of macrophage-enriched central nervous system aggregate cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Multiple sclerosis in sibling pairs: an analysis of 250 families

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Genetic basis for clinical expression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Suggestive Evidence for Association of Human Chromosome 18q12-q21 and Its Orthologue on Rat and Mouse Chromosome 18 With Several Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

HLA-DRB1 and disease outcome in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Association of a null mutation in the CNTF gene with early onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

APOE genotype is a major predictor of long-term progression of disability in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

APOE genotypes and disease severity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

The CTLA-4 gene is associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

HLA-DR15 and age at onset in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

The capillaries in acute and subacute multiple sclerosis plaques: A morphometric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Patterns of blood-brain barrier breakdown in inflammatory demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Multisequence MRI in clinically isolated syndromes and the early development of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Whole brain volume changes in patients with progressive MS treated with cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Antigen analogs/MHC complexes as specific T cell receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

CTLA-4: a negative regulator of autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Myelin Basic Protein–specific T Helper 2 (Th2) Cells Cause Experimental Autoimmune Encephalomyelitis in Immunodeficient Hosts Rather than Protect Them from the Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Late complications of immune deviation therapy in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Regulation of immune responses by TGF-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

TGF-beta: a balancing act.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

T cell vaccination in multiple sclerosis: results of a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900223-5

7 January 2021

10.1016/S1474-4422(02)00223-5

Identifiers

DOI

1 reference

26 June 2017

1 reference